Search results for "aspergillosis"

showing 10 items of 61 documents

PKSP-dependent reduction of phagolysosome fusion and intracellular kill of Aspergillus fumigatus conidia by human monocyte-derived macrophages.

2002

Summary Previously, we described the isolation of an Aspergillus fumigatus mutant producing non-pigmented conidia, as a result of a defective polyketide synthase gene, pksP (polyketide synthase involved in pigment biosynthesis). The virulence of the pksP mutant was attenuated in a murine animal infection model and its conidia showed enhanced susceptibility towards damage by monocytes in vitro. Because macrophage-mediated killing is critical for host resistance to aspergillosis, the interaction of both grey-green wild-type conidia and white pksP mutant conidia with human monocyte-derived macrophages (MDM) was studied with respect to intracellular processing of ingested conidia. After phagocy…

PhagocytosisImmunologyMutantVirulenceMicrobiologyPhagolysosomeMonocytesMicrobiologyAspergillus fumigatusConidiumCell FusionPhagocytosisMultienzyme ComplexesVirologyPhagosomesAspergillosisHumansskin and connective tissue diseasesCells CulturedPhagosomebiologyAspergillus fumigatusMacrophagesfungirespiratory systembiology.organism_classificationAcridine OrangeIntracellularCellular microbiology
researchProduct

Surgical management of invasive pulmonary aspergillosis in neutropenic patients.

1997

Background The aim of our study was to clarify the indications for operation in invasive pulmonary aspergillosis. Methods Nineteen patients with hematologic malignancy, in whom invasive pulmonary aspergillosis developed during the course of neutropenia, had operations. Neutropenia lasted 28 days (range, 15 to 45 days). The preoperative diagnosis of invasive pulmonary aspergillosis was based on computed tomographic scan findings (halo or air crescent signs). Results Eight patients underwent emergency operations, before marrow recovery, for prevention of massive hemoptysis. The criterion for operation was an aspergillosis lesion that contacted the pulmonary artery on computed tomography. A lo…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyHemoptysisNeutropeniaAdolescentNeutropeniaOpportunistic InfectionsAspergillosismedicine.arteryMedicineAspergillosisHumansChildMycosisAgedLungLeukemiaLung Diseases Fungalbusiness.industryRespiratory diseaseLength of StayMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureChild PreschoolPulmonary arteryAcute DiseaseSurgeryFemaleCardiology and Cardiovascular MedicineComplicationbusinessMultiple MyelomaWedge resection (lung)The Annals of thoracic surgery
researchProduct

Pseudomembranous invasive tracheobronchial aspergillosis.

2004

Invasive aspergillus tracheobronchitis is a rare infectious complication in severely immunocompromised patients who are generally neutropenic with haematological diseases, AIDS, or after solid organ transplantation. However, a few cases have been reported with no apparent severe compromise in the host defences.1 Aspergillus tracheobronchitis varies from localised tracheobronchitis …

Pulmonary and Respiratory MedicineMalePathologymedicine.medical_specialtyTracheal Diseasesmedicine.diagnostic_testbusiness.industryInvasive Aspergillus tracheobronchitismacromolecular substancesAspergillosismedicine.diseaseImages in ThoraxAspergillus tracheobronchitisBronchoscopyTracheobronchitisInfectious complicationBronchoscopymedicineBronchitisAspergillosisHumansSolid organ transplantationbusinessBronchitisAgedThorax
researchProduct

Pulmonary aspergilloma in a patient with AIDS.

1995

Aspergillus infections are rare in the course of AIDS. They mostly occur as invasive destructive disease in patients with severe CD4 cell depletion. An unusual case of a homosexual AIDS patient who developed a pulmonary aspergilloma is presented.

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyPathologyAIDS-Related Opportunistic InfectionsAspergillosisAcquired immunodeficiency syndrome (AIDS)Amphotericin BmedicineAspergillosisHumansskin and connective tissue diseasesMycosisLungAIDS-Related Opportunistic InfectionsLung Diseases Fungalbusiness.industryAspergillus fumigatusRespiratory diseaseMiddle Agedmedicine.diseaseDermatologymedicine.anatomical_structureItraconazoleComplicationbusinessAspergillomaResearch Article
researchProduct

Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.

2009

ABSTRACT We investigated the effects of anidulafungin alone and in combination with amphotericin B against Aspergillus fumigatus . Indifference was the only type of interaction observed in vitro. Anidulafungin at 1 and 5 mg/kg of body weight/day, amphotericin B at 1 mg/kg/day, and combination therapy prolonged the survival of mice with invasive aspergillosis. Anidulafungin at 5 mg/kg/day, alone and in combination with amphotericin B, reduced the kidney fungal burden. Overall, the combination was not superior to the most active single drug.

Settore MED/07 - Microbiologia E Microbiologia ClinicaAntifungal AgentsCombination therapymedicine.drug_classAntibioticsMicrobial Sensitivity TestsPharmacologyAspergillosisAnidulafunginKidneyAspergillus fumigatusMicrobiologyEchinocandinsMicePharmacotherapyAmphotericin BAmphotericin BmedicineAnimalsAspergillosisPharmacology (medical)Experimental TherapeuticsPharmacologyAspergillusbiologyAspergillus fumigatusaspergillus anidulafungin amphotericin BBrainbiology.organism_classificationmedicine.diseasebacterial infections and mycosesInfectious DiseasesAnidulafunginDrug Therapy Combinationmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Invasive maxillary sinus aspergillosis: a case report successfully treated with voriconazole and surgical debridement

2014

Introduction: Invasive aspergillosis of the paranasal sinuses is a rare disease and often misdiagnosed; however, its incidence has seen substancial growth over the past 2 decades. Definitive diagnosis of these lesions is based on histological examination and fungal culture. Case Report: An 81-year-old woman with a history of pain in the left maxillary region is presented. The diagnosis was invasive maxillary aspergillosis in immunocompetent patient, which was successfully treated with voriconazole and surgical debridement. Possible clinical manifestations, diagnostic imaging techniques and treatment used are discussed. Since the introduction of voriconazole, there have been several reports …

VoriconazoleAntifungalmedicine.medical_specialtyMaxillary sinusbusiness.industrymedicine.drug_classSurgical debridementCase ReportOdontología:CIENCIAS MÉDICAS [UNESCO]Aspergillosismedicine.diseaseCiencias de la saludSurgerymedicine.anatomical_structureParanasal sinusesUNESCO::CIENCIAS MÉDICASMedicineOral SurgerybusinessGeneral Dentistrymedicine.drugRare diseaseHistological examination
researchProduct

Dose Escalation of Caspofungin for Invasive Aspergillosis - A Phase II Trial

2010

Abstract Abstract 2309 Objectives. Treatment of invasive aspergillosis (IA) fails in up to 50% of all cases and the mortality rate is at least 30%. Antifungal combination treatment has not been proven to be beneficial and dose escalation with liposomal amphotericin B did not improve outcome. New approaches are needed for patients with severe immunosuppression. Methods. Escalating high dosages of caspofungin were investigated in IA defined according to modified EORTC/MSG criteria. The tested cohort of patients received 70mg, 100mg, 150mg or 200mg QD, 8 patients each were to receive caspofungin first-line treatment for proven/probable IA for up to 28 days. Dose limiting toxicity was defined a…

Voriconazolemedicine.medical_specialtyDosebusiness.industryMortality rateImmunologyCell BiologyHematologyAspergillosismedicine.diseaseBiochemistrySurgerychemistry.chemical_compoundchemistryInternal medicineToxicityCohortmedicineCaspofunginAdverse effectbusinessmedicine.drugBlood
researchProduct

Voriconazole and the liver.

2015

Voriconazole is an azole useful for the prophylaxis and the treatment of aspergillosis and other fungal infections in immunosuppressed subjects, as those found in aplasia after aggressive polychemotherapy treatments, after hematopoietic stem cell, liver or lung transplantation. Its administration in therapeutic doses lead to extremely varied serum levels from patient to patient and even to the same patient. The explanations are varied: nonlinear pharmacokinetics, certain patient-related factors, including genetic polymorphisms in the cytochrome P450 2C19 gene, the kidney and liver function, simultaneous administration with other drugs metabolised by the same cytochrome. It is recommended to…

Voriconazolemedicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryCYP2C19Pharmacologymedicine.diseaseAspergillosisGastroenterologyEditorialCholestasisTherapeutic drug monitoringInternal medicineToxicitymedicineLiver functionbusinessAdverse effectmedicine.drugWorld journal of hepatology
researchProduct

Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients

2003

Patients with severe neutropenia lasting for more than 10 days, who develop fever and pulmonary infiltrates, are at high risk of treatment failure and infection-related death, under conventional broad-spectrum antibiotics. Early supplementation by a systemic antifungal therapy active against Aspergillus spp. has been shown to markedly improve their clinical outcome. Prognosis is significantly influenced by early identification of lung infiltrates by means of high-resolution thoracic computed tomography. Non-culture based diagnostic procedures using a highly sensitive Sandwich ELISA assay to detect circulating galactomannan, or PCR techniques to amplify circulating fungal DNA, may facilitate…

Voriconazolemedicine.medical_specialtyPathologymedicine.diagnostic_testbusiness.industryRespiratory diseaseHematologyGeneral MedicineNeutropeniamedicine.diseaseAspergillosisGastroenterologyBronchoalveolar lavageAmphotericin B deoxycholateInternal medicinemedicinebusinessFebrile neutropeniaMycosismedicine.drugAnnals of Hematology
researchProduct

Combination therapy in a model of pulmonary aspergillosis

2009

Summary. The current treatment for pulmonary aspergillosis, amphotericin B, is toxic and not always effective. This study was done to evaluate combinations of amphotericin B with other agents in an animal model of pulmonary aspergillosis. Sprague-Dawley rats were treated with cortisone acetate, infected intratracheally with 106 spores of Aspergillus fumigatus, and followed daily for survival. Mortality among controls started on day 2, and it was 80% by day seven, whereas therapy with amphotericin B resulted in survival of all animals. When given alone, ketoconazole, 5-fluorocytosine and rifampin did not improve survival. The combination of ketoconazole with amphotericin B resulted in comple…

biologyCombination therapyItraconazolebusiness.industryDermatologyGeneral MedicinePharmacologybiology.organism_classificationAspergillosismedicine.diseaseAspergillus fumigatusFlucytosineInfectious DiseasesAmphotericin BImmunologymedicineKetoconazolebusinessMycosismedicine.drugMycoses
researchProduct